Dr David Borenstein, LDN Radio Show 28 Dec 2016 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: Today we are joined by Dr. David Bornstein.  Thank you for joining us, David. 

Dr David Borenstein: Thank you for having me. 

Dr Darin Ingels, LDN Radio Show 2017 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Dr Darin Ingels shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.

Dr Brian Udell on Autism, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Dr Brian Udell shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.

Dr Brian Udell on Low Dose Naltrexone, LDN Radio Show 17 May 2017 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Today our guest would be Dr. Brian Udell who is the medical director of the Child Development Center of America in Florida.

Linda Elsegood: Thank you for joining us today Dr. Brian Udell!

Adriana - US: Autism (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

This evening I'm joined by Adriana. She's from the United States. Thank you for joining us, Adriana. Could you tell us your story, please?

Integrated Review of the Assessment of Newborns With Neonatal Abstinence Syndrome

J Obstet Gynecol Neonatal Nurs
08 June 2021
https://pubmed.ncbi.nlm.nih.gov/34116058/

Objective: To critically review and summarize current knowledge regarding the assessment of newborns with neonatal abstinence syndrome (NAS).

Safety and tolerability of Low-Dose Naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study

J Clin Gastroenterol
01 April 2014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586944/

Background
There is an unmet need for safe and effective medicines to treat children with Crohn’s disease. Recently, investigations have shown an association between endogenous opioid peptides and inflammatory cells.

Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment

Invest New Drugs
August 2013
https://pubmed.ncbi.nlm.nih.gov/23275062/

Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system

Discov Med
October 2014
https://www.discoverymedicine.com/Brian-Johnson-2/2014/10/fibromyalgia-autism-and-opioid-addiction-as-natural-and-induced-disorders-of-the-endogenous-opioid-hormonal-system/

Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause?

Med Hypotheses
February 2006
https://pubmed.ncbi.nlm.nih.gov/16759815/

Inducible nitric oxide synthase is thought to be responsible for inflammatory nitric oxide concentrations in the brains of patients with MS and those with autism. It is proposed that low-dose naltrexone reduces nitric oxide synthase, thus acts as an anti-inflammatory agent.